Roivant Sciences Ltd. engages in the biopharmaceutical business, which develops drug candidates Vants in subsidiary companies. Its Vant model enables a modular approach to the monetization of therapies through development, commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.